New Benchmarks for Speed, Sensitivity and Performance Are Accelerating the
Adoption of Mass Spectrometry in Clinical, Biotech, Environmental and
Pharmaceutical Applications
WALTHAM, Mass., May 30 /PRNewswire-FirstCall/ -- Thermo Electron
Corporation (NYSE: TMO), the world leader in analytical instruments, has
launched several new liquid chromatography/mass spectrometry (LC/MS)
advancements at the ASMS Conference on Mass Spectrometry in Seattle,
Washington this week: the Accela(TM) High Speed Chromatography System, the
LTQ XL(TM) Linear Ion Trap Mass Spectrometer with Electron Transfer
Dissociation (ETD) for proteomics, the TSQ Quantum(TM) Access Triple
Quadrupole Mass Spectrometer and patented FAIMS Technology for high
sensitivity LC/MS/MS quantitation. These new products, along with novel
software solutions also being launched, set new benchmarks for speed,
sensitivity and performance and further accelerate adoption of Thermo's
mass spectrometry technology among commercial and academic researchers in
the clinical, biotech, environmental and pharmaceutical fields.
"Our customers demand solutions that dramatically streamline or
automate their workflows, rapidly analyze volumes of data, and pave the way
for the introduction of mass spectrometry beyond the research lab into
hospitals, clinics and smaller lab settings around the world," said Ian
Jardine, vice president, global research and development, Thermo Electron.
"Over the past 12 months, no company has delivered mass spectrometry
innovation at a faster pace than Thermo, and our goal is to continue
setting the bar for performance for years to come."
Thermo's new advancements launched at ASMS include:
New Accela High Speed Chromatography System is designed to operate from
conventional to ultra-high pressures, providing fast, efficient separations
that seamlessly integrate with Thermo's ultra fast scanning mass
spectrometers. Accela lets users achieve shorter run times with excellent
peak symmetry and superior data quality. The system is designed to meet the
analytical needs of LC and LC/MS users working in drug development,
discovery, QA/QC, academic, and food and beverage laboratories.
New LTQ XL Linear Ion Trap Mass Spectrometer significantly extends the
benefits of Thermo's successful LCQ/LTQ family of ion trap mass
spectrometers. The system is designed for drug discovery and proteomic
applications, specifically to accelerate screening for drugs, their
metabolites, and degradation products. The new instrument includes a number
of new advanced features including the optional and revolutionary ETD
technique for 1) mapping of post-translational modification (PTM) sites, 2)
allowing more comprehensive proteomic sample profiling, and 3) fragmenting
and analyzing large peptide fragments as well as intact proteins.
New TSQ Quantum Access Triple Quadrupole Mass Spectrometer is designed
for fast, efficient and confident sample analysis in the environmental and
food safety markets. It features QED-MS/MS (Quantitation Enhanced by
Data-dependant MS/MS) for simultaneously performing quantitative analysis
and generating rich product ion spectra for compound identification.
New FAIMS (High-Field Asymmetric Ion Mobility Mass Spectrometry)
technology for high-sensitivity bioanalysis, is an option available with
Thermo's TSQ Quantum(TM) triple quadrupole mass spectrometers. Developed
through the R&D efforts at Ionalytics, which Thermo acquired in August of
2005, the patented technology has been demonstrated to help in the
development of LC/MS/MS methods for drug quantitation by improving analyte
selectivity in complex sample analyses. Jardine continued, "We believe the
addition of FAIMS will contribute tremendously to our customer's ability to
push their detection limits even further. This is critical to the
acceleration of drug discovery research."
New advanced software packages, including SIEVE, support the critical
discovery of protein biomarkers using Thermo's mass spectrometers. Created
in collaboration with the Massachusetts General Hospital at the Biomarker
Research Initiatives in Mass Spectrometry (BRIMS) center, SIEVE is a
label-free differential expression analysis software offering an automated
workflow to compare LC/MS analyses from large sample populations. Combined
with the advanced capabilities of LTQ FT Ultra, as well as LTQ
Orbitrap(TM), the system provides exceptional high-resolution and accurate
mass data that allows for automated data processing to conclusively
identify and quantitate new protein biomarkers. Thermo's other software
introductions include: the powerful new MetWorks(TM) integrated acquisition
and analysis; BioWorks(TM) 3.3 for quantitative proteomics; ProSightPC(TM);
as well as highly stable software like QuickQuan(TM), LCQUAN(TM) 2.5,
Watson(TM) LIMS and Galileo LIMS.
About Thermo Electron
Thermo Electron Corporation is the world leader in analytical
instruments. Our instrument solutions enable our customers to make the
world a healthier, cleaner and safer place. Thermo's Life and Laboratory
Sciences segment provides analytical instruments, scientific equipment,
services and software solutions for life science, drug discovery, clinical,
environmental and industrial laboratories. Thermo's Measurement and Control
segment is dedicated to providing analytical instruments used in a variety
of manufacturing processes and in-the-field applications, including those
associated with safety and homeland security. For more information, visit
http://www.thermo.com.
Various remarks that we may make about the company's future
expectations, plans and prospects constitute forward-looking statements for
purposes of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995. Actual results may differ materially from
those indicated by these forward-looking statements as a result of various
important factors, including those discussed in our most recent Form 10-Q
under the caption "Risk Factors," which is on file with the Securities and
Exchange Commission and available in the "Investors" section of our website
under the heading "SEC Filings." These include risks and uncertainties
relating to: the need to develop new products and adapt to significant
technological change; implementation of strategies for improving internal
growth; use and protection of intellectual property; dependence on
customers' capital spending policies and government funding policies;
realization of potential future savings from new productivity initiatives;
dependence on customers that operate in cyclical industries; general
worldwide economic conditions and related uncertainties; the effect of
changes in governmental regulations; exposure to product liability claims
in excess of insurance coverage; implementation of our branding strategy;
identification, completion and integration of new acquisitions and
potential impairment of goodwill from previous acquisitions; retention of
contingent liabilities from businesses we sold; and the effect of exchange
rate fluctuations on international operations. While we may elect to update
forward-looking statements at some point in the future, we specifically
disclaim any obligation to do so, even if our estimates change and,
therefore, you should not rely on these forward-looking statements as
representing our views as of any date subsequent to today.
Media Contact Information: Investor Contact Information:
Lori Gorski Kenneth J. Apicerno
Phone: 781-622-1242 Phone: 781-622-1111
E-mail: lori.gorski@thermo.com E-mail: ken.apicerno@thermo.com
Website: http://www.thermo.com
SOURCE Thermo Electron Corporation
 back to top
Related links:
http://www.thermo.com/
http://www.prnewswire.com/comp/877850.html/
CONTACT:
Lori Gorski, Media Contact, +1-781-622-1242,
lori.gorski@thermo.com, or Kenneth J. Apicerno, +1-781-622-1111,
ken.apicerno@thermo.com, both of Thermo Electron Corporation
|
